Myra EB Systems — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Myra EB Systems is a private, early-stage company founded in 2017, headquartered in San Diego, CA. It operates as a platform company, offering an AI and cloud-based software suite (DrugTX.AI) designed to optimize pharmaceutical operations from clinical trials to manufacturing. The company appears to be pre-revenue or in early revenue, focusing on a SaaS/software licensing model for its modular applications. Its mission centers on utilizing AI and VR to improve drug development outcomes and transform life sciences operations.

AI / Machine Learning

Technology Platform

DrugTX.AI: An AI and cloud-based modular software suite for pharmaceutical operations, covering clinical trial design/analytics, manufacturing optimization, supply chain management, and VR-based training.

Opportunities

The growing demand for AI to reduce drug development costs and timelines presents a massive market.

The modular platform allows entry into multiple high-value segments (clinical, manufacturing, training) within pharma.

Partnerships, like the MLSC training program, provide validation and a path to early adoption.

Risk Factors

Faces intense competition from both AI-native biotechs and large established tech/CRO firms.

Value is dependent on integration with complex client IT systems and access to high-quality data.

AI tools in regulated environments may face scrutiny, lengthening sales cycles.

Competitive Landscape

Competes with broad AI drug discovery platforms (e.g., Recursion, Exscientia), specialized clinical trial tech companies (e.g., Unlearn.AI), manufacturing IoT platforms, and large life-science software vendors (e.g., Veeva). Differentiation hinges on the integrated suite covering the full drug development lifecycle.

More companies in AI / Machine Learning →More companies in United States →